Among these studies, a clinical trial of the H4R antagonist ZPL-3893787 in AD patients proved effectiveness through significantly higher reduction of eczema area severity index, and SCORAD compared with placebo [17]. This evidence concerns the gene HRH4 and Eczematoid dermatitis.